Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Other Current Liabilities
Apontis Pharma AG
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Apontis Pharma AG
XETRA:APPH
|
Other Current Liabilities
€238k
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ATAI Life Sciences NV
NASDAQ:ATAI
|
Other Current Liabilities
$715k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Bayer AG
XETRA:BAYN
|
Other Current Liabilities
€16.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
9%
|
|
![]() |
Merck KGaA
XETRA:MRK
|
Other Current Liabilities
€5.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
![]() |
Dermapharm Holding SE
XETRA:DMP
|
Other Current Liabilities
€161.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
![]() |
PharmaSGP Holding SE
XETRA:PSG
|
Other Current Liabilities
€6.5m
|
CAGR 3-Years
29%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Other Current Liabilities?
Other Current Liabilities
238k
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Other Current Liabilities amounts to 238k EUR.
What is Apontis Pharma AG's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
-39%
Over the last year, the Other Current Liabilities growth was -61%. The average annual Other Current Liabilities growth rates for Apontis Pharma AG have been -39% over the past three years .